細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Suppressors Of Cytokine Signaling 3 (SOCS3) ,etc. by FLIA (Flow Luminescence Immunoassay)
ATOD4; CIS3; Cish3; MGC71791; SOCS-3; SSI-3; SSI3; Cytokine-inducible SH2 protein 3; STAT-induced STAT inhibitor 3
(注:?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) )
- 編號(hào)LMB684Ra
- 物種Rattus norvegicus (Rat,大鼠) 相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3.5h
- 檢測(cè)范圍0.01-10ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.003 ng/mL.
- 樣本類型Tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2702 ¥ 2806 ¥ 2962 ¥ 3170 ¥ 3377 ¥ 3689 ¥ 4157 計(jì)算器 ¥ 5196 添加到價(jià)格計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測(cè)細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 82-104 | 96 |
EDTA plasma(n=5) | 78-93 | 84 |
heparin plasma(n=5) | 83-103 | 91 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線性范圍即為稀釋后樣本中細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 91-99% | 86-97% | 84-104% | 86-102% |
EDTA plasma(n=5) | 93-103% | 95-102% | 93-101% | 87-95% |
heparin plasma(n=5) | 78-91% | 87-94% | 98-105% | 92-105% |
穩(wěn)定性
經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠)標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL,
37°C酶標(biāo)板振蕩器孵育90分鐘;
3. 磁吸甩干,加檢測(cè)溶液A100μL,37°C酶標(biāo)板振蕩器孵育60分鐘;
4. 磁吸洗板3次;
5. 加檢測(cè)溶液B100μL,37°C振動(dòng)孵育30分鐘;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠,其中的細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Rattus norvegicus (Rat,大鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPB684Ra01 | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB684Ra01 | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)多克隆抗體 | WB; IHC; ICC; IP. |
LAB684Ra71 | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
MAB684Ra21 | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)單克隆抗體 | WB; IHC; ICC; IP. |
SEB684Ra | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
MEB684Ra | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB684Ra | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
The Journal of Biological Chemistry | Human primary keratinocytes show a restricted ability to up-regulate suppressor of cytokine signaling (SOCS)3 compared to autologous macrophages [Jcb: 280370] |
The Journal of Biological Chemistry | Human Primary Keratinocytes Show Restricted Ability to Up-regulate Suppressor of Cytokine Signaling (SOCS)3 Protein Compared with Autologous Macrophages [PubMed: PMC3323061] |
Journal of Reproductive Immunology | What is the impact of Th1/Th2 ratio, SOCS3, IL17, and IL35 levels in unexplained infertility? [Pubmed: 24368037] |
The Journal of Immunology | Alveolar Epithelial Cell–Derived Prostaglandin E2?Serves as a Request Signal for Macrophage Secretion of Suppressor of Cytokine Signaling 3 during Innate Inflammation [Pubmed:27183597] |
Scientific Reports | The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway [pubmed:28970500] |
Journal of Immunological Methods | Endogenous peroxidases in sputum interfere with horse-radish peroxidase-based ELISAs. [pubmed:29154772] |
Turkish?Journal Of?Medical?Sciences | The impact of plasma SOCS3 levels and endometrial leukocytes on unexplained infertility [Pubmed:29914245] |
Novel trajectories of Bromocriptine antidiabetic action: Leptin-IL-6/JAK2/p-STAT3/SOCS3, p-IR/p-AKT/GLUT4, PPARγ/Adiponectin, Nrf2/PARP-1, and GLP-1 [articles:10.3389] | |
JCI Insight | Alveolar macrophage secretion of vesicular SOCS3 represents a platform for lung cancer therapeutics [Pubmed: 31619584] |
European Journal of Pharmacology | Olmesartan attenuates type 2 diabetes-associated liver injury: Cross-talk of AGE/RAGE/JNK, STAT3/SCOS3 and RAS signaling pathways [Pubmed: 32067934] |
FASEB JOURNAL | Resident alveolar macrophage‐derived vesicular SOCS3 dampens allergic airway inflammation [Pubmed: 32030817] |
molecular immunology | SOCS3-deficient lung epithelial cells uptaking neutrophil-derived SOCS3 worsens lung influenza infection [Pubmed: 32645550] |
Experimental and Therapeutic Medicine | Changes and clinical significance of serum inflammatory factors in the treatment of pregnancy hypertension syndrome with magnesium sulfate combined with … [Pubmed: 32742411] |
NEUROCHEMICAL RESEARCH | Modulation of the Nitric Oxide/BH4 Pathway Protects Against Irradiation-Induced Neuronal Damage [33755856] |
BIOMEDICINE & PHARMACOTHERAPY | Potential contribution of ELISA and LFI Assays to assessment of the oxidative stress condition based on 8-oxodG biomarker [33957564] |